[1]CurrentPatentAssignee:PFIZERINC-WO2013/132376,2013,A1Locationinpatent:Page/Pagecolumn259-260
[2]Johnson,TedW.;Richardson,PaulF.;Bailey,Simon;Brooun,Alexei;Burke,BenjaminJ.;Collins,MichaelR.;Cui,J.Jean;Deal,JudithG.;Deng,Ya-Li;Dinh,Dac;Engstrom,LarsD.;He,Mingying;Hoffman,Jacqui;Hoffman,RobertL.;Huang,Qinhua;Kania,RobertS.;Kath,JohnC.;Lam,Hieu;Lam,JustineL.;Le,PhuongT.;Lingardo,Laura;Liu,Wei;McTigue,Michele;Palmer,CynthiaL.;Sach,NealW.;Smeal,Tod;Smith,GrahamL.;Stewart,AlbertE.;Timofeevski,Sergei;Zhu,Huichun;Zhu,Jinjiang;Zou,HelenY.;Edwards,MartinP.[JournalofMedicinalChemistry,2014,vol.57,#11,p.4720-4744]
[3]CurrentPatentAssignee:PFIZERINC-WO2014/207606,2014,A1Locationinpatent:Page/Pagecolumn37-38
[4]Elleraas,Jeff;Ewanicki,Jason;Johnson,TedW.;Sach,NealW.;Collins,MichaelR.;Richardson,PaulF.[AngewandteChemie-InternationalEdition,2016,vol.55,#11,p.3590-3595][Angew.Chem.,2016,vol.128,p.3654-3659,6]
[1]CurrentPatentAssignee:PFIZERINC-WO2014/207606,2014,A1Locationinpatent:Page/Pagecolumn60
[1]CurrentPatentAssignee:PFIZERINC-WO2014/207606,2014,A1
[1]CurrentPatentAssignee:PFIZERINC-WO2017/21823,2017,A1Locationinpatent:Page/Pagecolumn18
[2]CurrentPatentAssignee:PFIZERINC-WO2014/207606,2014,A1Locationinpatent:Page/Pagecolumn59-60
[3]Li,Bryan;Li,Ruizhi;Dorff,Peter;McWilliams,J.Christopher;Guinn,RobertM.;Guinness,StevenM.;Han,Lu;Wang,Ke;Yu,Shu[JournalofOrganicChemistry,2019,vol.84,#8,p.4846-4855]
[4]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2019/209633,2019,A1Locationinpatent:Paragraph00210;00236
[1]CurrentPatentAssignee:TELIGENE-WO2016/26423,2016,A1Locationinpatent:Paragraph0045;0046
[2]CurrentPatentAssignee:TELIGENE-US2017/216264,2017,A1Locationinpatent:Paragraph0064-0068
Title: Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.
Journal: Translational lung cancer research 20160601
Title: Resistance: Crizotinib makes a comeback.
Journal: Nature reviews. Cancer 20160201
Title: Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Journal: The New England journal of medicine 20160107
Title: PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20150317
Title: Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Journal: Journal of medicinal chemistry 20140612
Title: Johnson TW, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo,3-h,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014 Jun 12;57(11):4720-44.
Title: Zou HY, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking PF-02341066-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8
